Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

Clinical advances of siRNA therapeutics

siRNA therapeutics: a clinical reality

Strategies, design, and chemistry in siRNA delivery systems

Current progress of siRNA/shRNA therapeutics in clinical trials

The current state and future directions of RNAi-based therapeutics

The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market

RNA interference in the era of nucleic acid therapeutics

Therapeutic siRNA: State-of-the-Art and Future Perspectives

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry

Recent Advances in Engineering Carriers for siRNA Delivery

Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review

siRNA therapeutics: insights, challenges, remedies and future prospects

RNA Therapeutics - Research and Clinical Advancements

RNAi-based drug design: considerations and future directions

The Growing Class of Novel RNAi Therapeutics

Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside

RNA-based Therapeutics: an Overview and Prospectus

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

Synthetic SiRNA Delivery: Progress and Prospects

siRNAs as potential drugs.